Our work found that elevated FBXO32 levels promoted K48‐linked PHLPP2 polyubiquitination at K592 and K942 residues, leading to PHLPP2 degradation, PI3K–AKT signaling pathway activation, and subsequent malignant HCC progression. The gene discussed is FBXO32; the disease is hepatocellular carcinoma.